blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2091944

EP2091944 - SUBSTITUTED BICYCLOCARBOXYAMIDE COMPOUNDS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  23.03.2012
Database last updated on 11.04.2026
Most recent event   Tooltip04.10.2013Lapse of the patent in a contracting state
New state(s): HU		published on 06.11.2013  [2013/45]
Applicant(s)For all designated states
Pfizer Inc.
235 East 42nd Street
New York, NY 10017 / US
For all designated states
Evotec AG
Schnackenburgallee 114
22525 Hamburg / DE
[2011/27]
Former [2011/20]For all designated states
Pfizer Inc.
235 East 42nd Street
New York, NY 10017 / US
For all designated states
Renovis, Inc.
2 Corporate Drive
South San Francisco, CA 94080 / US
Former [2009/35]For all designated states
Pfizer, Inc.
235 East 42nd Street
New York, NY 10017 / US
For all designated states
Renovis, Inc.
2 Corporate Drive
South San Francisco, CA 94080 / US
Inventor(s)01 / CALABRESE, Andrew Antony
Pfizer Global Research and Development Ramsgate Road
Sandwich, Kent CT13 9NJ / GB
02 / DUNCTON, Matthew Alexander James
Renovis Inc. 2 Corporate Dr.
San Francisco, CA 94080 / US
03 / FUTATSUGI, Kentaro
Pfizer Global Research and Development Nagoya Laboratories 5-2, Taketoyo-cho
Chita-gun Aichi-ken 470-2393 / JP
04 / HIRANO, Misato
Pfizer Global Research and Development Nagoya Laboratories 5-2, Taketoyo-cho
Chita-gun Aichi-ken 470-2393 / JP
05 / NAGAYAMA, Satoshi
Pfizer Global Research and Development Nagoya, Laboratories 5-2, Taketoyo-cho
Chita-gun Aichi-ken 470-2393 / JP
06 / ANDO, Koji
Pfizer Global Research and Development Nagoya Laboratories, 5-2 Taketoyo-cho Chita-gun
Aichi-ken 470-2393 / JP
 [2009/35]
Representative(s)Lane, Graham Mark Hamilton, et al
Pfizer
ATTENTION: ADDRESS INACTIVE - USE ASS-NR - CDR / FR
[N/P]
Former [2012/09]Lane, Graham Mark Hamilton, et al
Pfizer
European Patent Department
23-25, avenue du Docteur Lannelongue
75668 Paris Cedex 14 / FR
Former [2009/35]Hodge, Emma Jane
Pfizer Limited European Patent Department Ramsgate Road
Sandwich, Kent CT13 9NJ / GB
Application number, filing date07825705.209.11.2007
[2009/35]
WO2007IB03559
Priority number, dateUS20060866285P17.11.2006         Original published format: US 866285 P
US20070943933P14.06.2007         Original published format: US 943933 P
US20070983343P29.10.2007         Original published format: US 983343 P
[2009/35]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2008059370
Date:22.05.2008
Language:EN
[2008/21]
Type: A2 Application without search report 
No.:EP2091944
Date:26.08.2009
Language:EN
The application published by WIPO in one of the EPO official languages on 22.05.2008 takes the place of the publication of the European patent application.
[2009/35]
Type: B1 Patent specification 
No.:EP2091944
Date:18.05.2011
Language:EN
[2011/20]
Search report(s)International search report - published on:EP24.07.2008
ClassificationIPC:C07D401/12, C07D231/12, A61K31/415, A61K31/4155, A61K31/47
[2009/35]
CPC:
C07D401/12 (EP,US); A61P1/00 (EP); A61P1/04 (EP);
A61P1/08 (EP); A61P11/00 (EP); A61P11/02 (EP);
A61P11/06 (EP); A61P13/00 (EP); A61P13/10 (EP);
A61P13/12 (EP); A61P15/02 (EP); A61P17/02 (EP);
A61P19/02 (EP); A61P25/00 (EP); A61P25/04 (EP);
A61P25/06 (EP); A61P29/00 (EP); A61P3/04 (EP);
A61P3/10 (EP); A61P43/00 (EP); A61P9/00 (EP);
A61P9/10 (EP); C07D231/12 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2009/35]
TitleGerman:SUBSTITUIERTE BICYCLOCARBONSÄUREAMIDVERBINDUNGEN[2009/35]
English:SUBSTITUTED BICYCLOCARBOXYAMIDE COMPOUNDS[2009/35]
French:COMPOSÉS BICYCLOCARBOXYAMIDES SUBSTITUÉS[2009/35]
Entry into regional phase17.06.2009National basic fee paid 
17.06.2009Designation fee(s) paid 
17.06.2009Examination fee paid 
Examination procedure17.06.2009Examination requested  [2009/35]
02.11.2009Despatch of a communication from the examining division (Time limit: M06)
30.04.2010Reply to a communication from the examining division
17.09.2010Despatch of a communication from the examining division (Time limit: M04)
02.12.2010Reply to a communication from the examining division
05.01.2011Communication of intention to grant the patent
05.04.2011Fee for grant paid
05.04.2011Fee for publishing/printing paid
Opposition(s)21.02.2012No opposition filed within time limit [2012/17]
Fees paidRenewal fee
30.11.2009Renewal fee patent year 03
30.11.2010Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT18.05.2011
BE18.05.2011
CY18.05.2011
CZ18.05.2011
DK18.05.2011
EE18.05.2011
FI18.05.2011
HU18.05.2011
LT18.05.2011
LV18.05.2011
MT18.05.2011
NL18.05.2011
PL18.05.2011
RO18.05.2011
SE18.05.2011
SI18.05.2011
SK18.05.2011
TR18.05.2011
BG18.08.2011
GR19.08.2011
IS18.09.2011
PT19.09.2011
LU09.11.2011
CH30.11.2011
LI30.11.2011
MC30.11.2011
[2013/45]
Former [2013/44]AT18.05.2011
BE18.05.2011
CY18.05.2011
CZ18.05.2011
DK18.05.2011
EE18.05.2011
FI18.05.2011
LT18.05.2011
LV18.05.2011
MT18.05.2011
NL18.05.2011
PL18.05.2011
RO18.05.2011
SE18.05.2011
SI18.05.2011
SK18.05.2011
TR18.05.2011
BG18.08.2011
GR19.08.2011
IS18.09.2011
PT19.09.2011
LU09.11.2011
CH30.11.2011
LI30.11.2011
MC30.11.2011
Former [2013/29]AT18.05.2011
BE18.05.2011
CY18.05.2011
CZ18.05.2011
DK18.05.2011
EE18.05.2011
FI18.05.2011
LT18.05.2011
LV18.05.2011
MT18.05.2011
NL18.05.2011
PL18.05.2011
RO18.05.2011
SE18.05.2011
SI18.05.2011
SK18.05.2011
BG18.08.2011
GR19.08.2011
IS18.09.2011
PT19.09.2011
LU09.11.2011
CH30.11.2011
LI30.11.2011
MC30.11.2011
Former [2013/25]AT18.05.2011
BE18.05.2011
CY18.05.2011
CZ18.05.2011
DK18.05.2011
EE18.05.2011
FI18.05.2011
LT18.05.2011
LV18.05.2011
MT18.05.2011
NL18.05.2011
PL18.05.2011
RO18.05.2011
SE18.05.2011
SI18.05.2011
SK18.05.2011
GR19.08.2011
IS18.09.2011
PT19.09.2011
LU09.11.2011
CH30.11.2011
LI30.11.2011
MC30.11.2011
Former [2013/14]AT18.05.2011
BE18.05.2011
CY18.05.2011
CZ18.05.2011
DK18.05.2011
EE18.05.2011
FI18.05.2011
LT18.05.2011
LV18.05.2011
MT18.05.2011
NL18.05.2011
PL18.05.2011
RO18.05.2011
SE18.05.2011
SI18.05.2011
SK18.05.2011
GR19.08.2011
IS18.09.2011
PT19.09.2011
CH30.11.2011
LI30.11.2011
MC30.11.2011
Former [2012/34]AT18.05.2011
BE18.05.2011
CY18.05.2011
CZ18.05.2011
DK18.05.2011
EE18.05.2011
FI18.05.2011
LT18.05.2011
LV18.05.2011
NL18.05.2011
PL18.05.2011
RO18.05.2011
SE18.05.2011
SI18.05.2011
SK18.05.2011
GR19.08.2011
IS18.09.2011
PT19.09.2011
CH30.11.2011
LI30.11.2011
MC30.11.2011
Former [2012/29]AT18.05.2011
BE18.05.2011
CY18.05.2011
CZ18.05.2011
DK18.05.2011
EE18.05.2011
FI18.05.2011
LT18.05.2011
LV18.05.2011
NL18.05.2011
PL18.05.2011
RO18.05.2011
SE18.05.2011
SI18.05.2011
SK18.05.2011
GR19.08.2011
IS18.09.2011
PT19.09.2011
MC30.11.2011
Former [2012/12]AT18.05.2011
BE18.05.2011
CY18.05.2011
CZ18.05.2011
DK18.05.2011
EE18.05.2011
FI18.05.2011
LT18.05.2011
LV18.05.2011
NL18.05.2011
PL18.05.2011
RO18.05.2011
SE18.05.2011
SI18.05.2011
SK18.05.2011
GR19.08.2011
IS18.09.2011
PT19.09.2011
Former [2012/01]AT18.05.2011
BE18.05.2011
CY18.05.2011
FI18.05.2011
LT18.05.2011
LV18.05.2011
NL18.05.2011
SE18.05.2011
SI18.05.2011
GR19.08.2011
IS18.09.2011
PT19.09.2011
PL26.09.2011
Former [2011/52]AT18.05.2011
CY18.05.2011
FI18.05.2011
LT18.05.2011
LV18.05.2011
SE18.05.2011
SI18.05.2011
GR19.08.2011
IS18.09.2011
PT19.09.2011
PL26.09.2011
Former [2011/50]CY18.05.2011
FI18.05.2011
LT18.05.2011
LV18.05.2011
SE18.05.2011
SI18.05.2011
GR19.08.2011
IS18.09.2011
PT19.09.2011
PL26.09.2011
Former [2011/49]CY18.05.2011
FI18.05.2011
LT18.05.2011
SE18.05.2011
GR19.08.2011
PT19.09.2011
Former [2011/48]LT18.05.2011
SE18.05.2011
PT19.09.2011
Former [2011/47]LT18.05.2011
PT19.09.2011
Cited inInternational search[A] WO03068749  (GLAXO GROUP LTD et al.) [A] 1-17 * claims 1,7,8 *
 [A] US2005165049  (HULME CHRISTOPHER et al.) [A] 1-17 * paragraph [0028] * * claim 1 *
 [A] WO2004108133  (VERTEX PHARMA et al.) [A] 1-17 * paragraph [0017] * * claim 1 *
 [A] WO2005021509  (ASTRAZENECA AB et al.) [A] 1-17 * examples 2.48,2.59,2.60,2.61,2.62,2.67 * * page 20, lines 25-27 * * claim 1 *
 [A] US6979686  (NARAIAN ASHOK S et al.) [A] 1-17 * column 389; examples examples,b-0037 * * column 659; examples b-1189 * * claims 1,41 *
 [A]   DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SIU, JASON ET AL: "A phase-switch purification approach for the expedient removal of tagged reagents and scavengers following their application in organic synthesis", XP002478714, retrieved from STN Database accession no. 2005:800492 [A] 1-17 * abstract *
 [A]   ORGANIC & BIOMOLECULAR CHEMISTRY , 3(17), 3140-3160 CODEN: OBCRAK; ISSN: 1477-0520, 2005
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.